Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gallein is a synthetic small-molecule xanthene dye (pyrogallol phthalein) that functions as a high-affinity inhibitor of G protein βγ (Gβγ) subunit–dependent signaling, disrupting the interaction of Gβγ with downstream effectors such as phosphoinositide 3-kinase γ (PI3Kγ) and thereby blocking PI3K and Rac1 activation, neutrophil chemotaxis, and related inflammatory responses.[1][2][3][5][7][8][10] Originally developed and used as a biological stain, acid–base indicator, and mordant dye, it has since been widely repurposed as a research tool compound in GPCR/G protein signaling, oncology, immunology, and cardiovascular models, where it demonstrates anticancer, anti-inflammatory, and cardioprotective activities in preclinical systems but is not an approved therapeutic drug.[1][2][3][5][7][8][10]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gallein.